Freenome (NASDAQ:FRNM) Raised to Strong-Buy at BTIG Research

Freenome (NASDAQ:FRNM) was upgraded by equities research analysts at BTIG Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. TD Cowen began coverage on Freenome in a report on Tuesday. They set a “buy” rating for the company. Leerink Partners assumed coverage on Freenome in a research note on Friday. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Freenome in a research note on Monday. They issued a “buy” rating and a $17.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy” and an average target price of $17.33.

Freenome Stock Performance

Shares of NASDAQ:FRNM opened at $13.00 on Monday. Freenome has a 12 month low of $9.97 and a 12 month high of $14.26.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.